Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice
NCT ID: NCT00922766
Last Updated: 2012-01-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
618 participants
OBSERVATIONAL
2009-05-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
NCT00435487
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
NCT00445328
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
NCT03280368
Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States
NCT04565977
Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
NCT00655122
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1.0
Dalteparin
Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dalteparin
Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Ahmedabad, Gujarat, India
Pfizer Investigational Site
Surat, Gujarat, India
Pfizer Investigational Site
Hisar, Haryana, India
Pfizer Investigational Site
Hisar, Haryana, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Manglore, Karnataka, India
Pfizer Investigational Site
Mysore, Karnataka, India
Pfizer Investigational Site
Nagpur, Maharahtra, India
Pfizer Investigational Site
Nashik, Maharahtra, India
Pfizer Investigational Site
Ambernath (E), Maharashtra, India
Pfizer Investigational Site
Nagpur, Maharashtra, India
Pfizer Investigational Site
Nagpur, Maharashtra, India
Pfizer Investigational Site
Nagpur, Maharashtra, India
Pfizer Investigational Site
Nagpur, Maharashtra, India
Pfizer Investigational Site
Nashik, Maharashtra, India
Pfizer Investigational Site
Nashik, Maharashtra, India
Pfizer Investigational Site
Nashik Road, Maharashtra, India
Pfizer Investigational Site
Nashik Road, Maharashtra, India
Pfizer Investigational Site
Thāne, Maharashtra, India
Pfizer Investigational Site
Bikaner, Rajasthan, India
Pfizer Investigational Site
Jaipur, Rajasthan, India
Pfizer Investigational Site
Jaipur, Rajasthan, India
Pfizer Investigational Site
Chennai, Tamil Nadu, India
Pfizer Investigational Site
Kolkata, West Bengal, India
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6301088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.